SDHC methylation in gastrointestinal stromal tumors (GIST): a case report

Background Gastrointestinal stromal tumors (GIST) recently have been recognized as a genetically and biologically heterogeneous disease. In addition to KIT or PDGFRA mutated GIST, mutational inactivation of succinate dehydrogenase (SDH) subunits has been detected in the KIT/PDGFRA wild-type subgroup, referred to as SDH deficient (dSDH). Even though most dSDH GIST harbor mutations in SDHx subunit genes, some are SDHx wild type. Epigenetic regulation by DNA methylation of CpG islands recently has been found to be an alternative mechanism underlying the lack of SDH complex in GIST. Case presentation We report a particular case of dSDH GIST, previously analyzed with microarrays and next-generation sequencing, for which no molecular pathogenetic events have been identified. Gene expression analysis showed remarkable down-modulation of SDHC mRNA with respect to all other GIST samples, both SDHA-mutant and KIT/PDGFRA-mutant GIST. By a bisulfite methylation assay targeted to 2 SDHC CpG islands, we detected hypermethylation of the SDHC promoter. Conclusion Herein we report an additional case of dSDH GIST without SDHx mutation but harboring hypermethylation in the SDHC promoter, thus confirming the complexity of the molecular background of this subtype of GIST. Electronic supplementary material The online version of this article (doi:10.1186/s12881-015-0233-7) contains supplementary material, which is available to authorized users.


Background
Gastrointestinal stromal tumors (GIST) recently have been recognized as a genetically and biologically heterogeneous disease [1]. In addition to KIT-or PDGFRAmutated GIST, mutational inactivation of succinate dehydrogenase (SDH) subunits has been detected in the KIT/PDGFRA wild-type subgroup. This latter type of GIST can be identified by negative staining of SDHB proteins and is defined as SDH-deficient (dSDH) GIST [2,3].
Epigenetic regulation by DNA methylation of CpG islands has been shown to play a relevant role in the pathogenesis of several cancers. The hypermethylation phenotype has been detected in dSDH GIST, and more recently evidence of the involvement of methylation of SDHC in this subgroup has been reported [4][5][6][7].
Herein we reported the molecular characterization of 1 case of dSDH GIST-analyzed with microarrays, next-generation sequencing, and bisulfite sequencing-identifying, as unique molecular pathogenic event, methylation of the SDHC promoter.

Case presentation
A 25-year-old woman had multifocal, epithelioid gastric GIST (CARE checklist is available as Additional file 1). KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 12, 14, and 18) molecular analysis did not show evidence of mutations. The clinical/pathological features matched well with those describing dSDH GIST (female sex, young age, and multifocal and epithelioid gastric GIST). Moreover, in a gene expression analysis previously reported (GSE20710), we showed that the expression profile of this tumor (GIST_21) was similar to the profile of 3 patients (GIST_07, GIST_10, and GIST_24) who we subsequently identified as having mutated SDHA [3,8]. To better characterize GIST_21, all SDHx subunits were sequenced by the Sanger method, but the analysis did not show any mutations.
To search for alterations that might not have been detected by Sanger sequencing, we performed paired-end whole exome sequencing of GIST_21 (see Additional file 2 for materials and methods), without finding any mutations in any SDHx coding sequences or flanking intronic regions. Exhaustive exome sequencing analysis revealed no pathogenic mutations in other GIST-related genes, such PDGFRA, BRAF, and neurofibromin 1, and only a nonsynonymous missense variant in exon 18 of KIT. This variant is described in the COSMIC database (COSM133780) in 1 case of malignant melanoma. Because the matched normal sample for this patient was not available, we were not able to determine if this KIT variant was somatic or germinal.
By gene expression analysis, we examined the expression levels of the 4 subunits of the SDH complex; as shown in Fig. 1a, we detected a remarkable downmodulation of SDHC mRNA in GIST_21 with respect to all other GIST samples, both SDHA-mutant and KIT/ PDGFRA-mutant GIST. Moreover, Western blot immunoassay showed that GIST_21 had normal SDHA but markedly decreased SDHB protein expression (Fig. 1b) and would be predicted to have a loss of SDH complex activity. Additionally, SNP6.0 genotyping on GIST_21 showed a normal karyotype, with no detectable loss of heterozygosity or chromosome 1q deletion [9].
Hypermethylation of the SDHC promoter region was recently associated with Carney triad-related GIST and dSDH GIST without SDHx mutation [6,7]. Thus, we designed a bisulfite methylation assay to look for potential epimutations in the 2 known CpG islands of the SDHC promoter regions, CpG17 and CpG27. This analysis was performed in 4 dSDH (including GIST_21 and 3 GIST without SDHx mutations) and in 8 KIT/PDGFRA-mutated GIST. Hypermethylation of the SDHC promoter was found only in GIST_21, and this alteration was detected in heterozygosis at all CpG sites (Fig. 1c). The methylated case showed a significant 0.63-fold decrease in SDHC mRNA expression level (P = 0.0001) in comparison with the 11 methylation-negative cases (Fig. 1d).

Discussion
Previous studies showed that all dSDH GIST are characterized by a genome-wide hypermethylation phenotype, but the downregulation of the SDH complex remains unexplained for those cases lacking mutations in the SDHx subunits. The case of dSDH GIST that we report here has not shown any molecular alterations in the SDHx complex nor have other pathogenetic events been detected by whole exome sequencing. Epigenetic modification of the SDHC promoter was the only pathogenetic event identified. Haller et al. [6] reported for the first time the presence of aberrant DNA methylation of the SDHC promoter in 4 patients with dSDH Carney triadrelated GIST that are known to lack SDHx mutations. More recently, Killian et al. [7] performed a genomewide methylation assay on 59 cases of dSDH GIST, selected on the basis of SDHB-negative immunostaining. They detected recurrent hypermethylation of the SDHC promoter in 94 % (15 of 16 cases) of the SDHx wild-type subgroup (ie, deficiency of the SDHB protein but no mutations in the coding region of any SDH subunits). This event was not confirmed outside of the SDHC promoter, in which there was no significant hypermethylation. In our cohort, SDHC epimutation was not detected in either SDHx-or KIT/PDGFRA-mutated GIST. This finding is consistent with those of previous reports [6,7], in which SDHC hypermethylation was found only in dSDH GIST without SDHx mutation. Moreover, Killian et al. [7] found that the SDHC methylation was mutually exclusive of mutations or loss of heterozygosity events in other SDHx subunits, with the exception of hemimethylation that was associated with heterozygous mutations of the SDHC gene (4 of 7 cases). In particular, the authors found 4 cases with monoallelic methylation of SDHC in compound heterozygosity with mutation of SDHC, consistent with the Knudson 2-hit model, whereas 3 cases were negative for any other alterations. The case we reported, GIST_21, could be part of this latter group, also confirming that the detection of partial methylation of SDHC could be a marker of the complete disassembly of the SDH complex through the down-modulation of SDHC and the consequent degradation of the SDHB protein.
The presence of additional undetected mutations or INDELs in SDHC was not likely because the Exome sequencing probes also covered the proximal SDHC promoter region and the single-nucleotide polymorphism array did not detect any copy number alterations. Otherwise, due to technical limitations of the sequencing technologies, we could not exclude the presence of other alterations in SDHC or other SDHx subunits that could lead to the complete absence of the SDHB protein (e.g., a mutation in a region not sufficiently covered by exome capture or a cryptic deletion inside the SDHC gene). However, considering the rarity and complexity of these molecular events, the clinical implications of these differences in SDH complex deregulation are still not completely known but probably are not associated with a different clinical profile and different behavior among the dSDH GIST cases.

Conclusion
In conclusion, herein we reported an additional case of dSDH GIST without SDHx mutation, but harboring hypermethylation in the SDHC promoter, thus confirming the relevance of an epigenomic event in this pathology. For this patient, no other molecular pathogenic event was detected. Our case may confirm the complexity of the molecular background of dSDH GIST by the integration of genomic and epigenomic assays using high-throughput technologies that helped to identify the specific mechanism of SDH complex inactivation underlying the loss of SDHB protein expression not driven by SDHx mutations in this subgroup of GIST.

Consent
Written informed consent was obtained from the patient for publication of this Case report. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
The authors declare that they have no competing interests.
Authors' contributions MU carried out the molecular genetic studies and sequence alignment and drafted the manuscript. AA contributed to the conception and design of the study and interpretation of the data and drafted the manuscript. VI carried out the bioinformatic analysis and interpretation of data and drafted the manuscript. MCH contributed to the conception of the study, revised and gave final approval of the manuscript. CLC contributed to interpretation of data, drafted the manuscript and gave final approval of the manuscript. MN contributed to the conception and design of the study and interpretation of data and drafted the manuscript. GR carried out the molecular genetic studies and drafted the manuscript GB contributed to the conception of the work, revised it critically and gave final approval of the manuscript. MAP contributed to the conception and design of the study and interpretation of data and drafted the manuscript. All authors read and approved the final manuscript.
Submit your next manuscript to BioMed Central and take full advantage of: